Across TCGA pan-cancer cohorts, MRPS23 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MRPS23 data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in uterine carcinosarcoma (UCS), where higher MRPS23 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MRPS23 expression acts as an unfavorable survival marker.
UCS, LUAD, and UCEC are the cancer types where MRPS23 Mutation most reproducibly stratifies survival.